Maria Orig, MD
Nephrology · Carrollton, GANPI 1225054216
Payments from drug & device makers
Across 113 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$344
- AstraZeneca$314
- Akebia Therapeutics Inc$308
- OPKO Pharmaceuticals, LLC$194
- Fresenius USA Marketing, Inc.$166
- Bayer$157
- plus $664 from 14 others
What the payments were for
- Food & beverage$1,99193%
- Education$1567%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 15 | $344 |
| AstraZeneca(2 entities) | 17 | $314 |
| Akebia Therapeutics Inc | 17 | $308 |
| OPKO Pharmaceuticals, LLC | 12 | $194 |
| Fresenius USA Marketing, Inc. | 9 | $166 |
| Bayer | 8 | $157 |
| Amgen(2 entities) | 6 | $137 |
| Aurinia Pharma U.S., Inc. | 5 | $135 |
| Vifor Pharma, Inc. | 4 | $78 |
| Alnylam Pharmaceuticals Inc. | 3 | $60 |
| Boehringer Ingelheim | 2 | $41 |
| Travere Therapeutics, Inc. | 6 | $39 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Novartis | 1 | $28 |
| Calliditas Therapeutics US Inc. | 1 | $23 |
| Mallinckrodt Enterprises LLC | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| Shire North American Group Inc | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Nxstage Medical, Inc. | 1 | $14 |
How this compares
$2,147 in reported general payments places this provider in the 50th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Labetalol Hcl | 11 | $1,179 |
| Metoprolol Succinate | 60 | $992 |
| Calcitriol | 75 | $979 |
| Losartan Potassium | 67 | $826 |
| Torsemide | 11 | $560 |
| Hydralazine Hcl | 55 | $436 |
| Furosemide | 62 | $418 |
| Potassium Chloride | 22 | $342 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 27 | $322 |
| Allopurinol | 39 | $307 |
| Nifedipine ErNifedipine | 21 | $305 |
| Lisinopril | 26 | $232 |
| Spironolactone | 21 | $138 |
| Amlodipine Besylate | 30 | $124 |
| Glimepiride | 17 | $109 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Carrollton
- James TumlinLawrenceville$19.8M
- Chinedu NwekeAcworth$3.9M
- Vinayak RamanathLagrange$3.1M
- Harold HubertAugusta$2.8M
- Tamorie SmithColumbus$1.9M
- Barton BrezinaAugusta$1.5M
- Frederic Rahbari OskouiAtlanta$1.5M
- Rajeev ChauhanColumbus$1.1M
- Sagar PanseMacon$1.1M
- Laura MulloyAugusta$891K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.